• A Study About Aromatic L-Amino Acid Decarboxylase Deficiency (AADC) in Pediatric Patients

    Official Title A Single-Stage, Adaptive, Open-Label Dose Escalation Safety Study of Adeno-Associated Virus Encoding Human Aromatic L-Amino Acid Decarboxylase (AAV2-hAADC) Administered by MR- guided Infusion into the Midbrain in Pediatric Patients with AADC Deficiency

    Purpose

    The overall objective of this study is to determine the safety and efficacy of AAV2-hAADC delivered to the substantia nigra pars compacta (SNc) and ventral tegmental area (VTA) in children with aromatic L-amino acid decarboxylase (AADC) deficiency, and to see if there is a demonstration of effective restoration of AADC function by assays of CSF neurotransmitter metabolites and F-DOPA PET imaging, as allowed by subject’s ability to travel to undergo follow-up visits.

    Could this study be right for you?

    Inclusion Criteria

    • Diagnosis of AADC deficiency from genetic test and CSF/blood enzyme test
    • Failed to derive adequate benefit from standard medical therapy as judged by presence of residual oculugyric crises and developmental delay.
    • Documented history of motor developmental delay, with inability to walk independently without support by age 18 months.
    • Both parents (or legal guardians) must give their consent for their child’s participation in the study unless (i.) one parent is deceased, unknown or incompetent; (ii.) one parent is not reasonably available; or (iii.) one parent has responsibility for the care and custody of the child.

    Inclusion Criteria varies, please contact Study Coordinator for more information.

    Exclusion Criteria

    • Presence of other significant medical or neurological conditions that would create an unacceptable operative or anesthetic risk.
    • Previous stereotactic neurosurgery.
    • Coagulopathy, or need for ongoing anticoagulant therapy.
    • Receipt of any investigational agent within 60 days prior to Baseline and during study participation.

    Exclusion Criteria varies, please contact Study Coordinator for more information.

    Age Range

    2 years and up

    Contact Information

  • Spinal Cord Stimulation and Small Fiber Peripheral Neuropathy

    Official Title Spinal Cord Stimulation and Small Fiber Peripheral Neuropathy

    Purpose

    The purpose of this study is to determine whether spinal cord stimulation (SCS) will reduce pain in patients with painful Diabetic Peripheral Neuropathy (DPN).

    Could this study be right for you?

    Inclusion Criteria:

    • Over 18 years old
    • Diagnosis of diabetic peripheral neuropathy refractory to treatment with gabapentin or pregabalin and at least 1 other class of analgesic
    • Diagnosis of medically refractory pain secondary to diabetic neuropathy
    • Presence of pain for 12 months

    Exclusion Criteria:

    • Severe medical comorbidities that, in the opinion of the surgeon, exclude the patient from surgical intervention
    • Spinal disease with severe spinal stenosis or spinal cord compression in the region of the proposed spinal cord stimulator lead placement
    • Coagulopathy that cannot be corrected
    • Unable to discontinue blood thinning medications

    Inclusion and Exclusion Criteria varies, please contact Study Coordinator.

    Age Range

    18 years and up

    Contact Information

    Brain and Spine Hospital
    Alex Price
    (614)685-8622
  • A Study for those with Treatment Resistant Epilepsy & Anxiety

    Official Title An open-label clinical trial evaluating the ExAblate Model 4000 Type-1 focused ultrasound unilateral thalamotomy for patients with treatment-refractory focal onset epilepsy and comorbid anxiety

    Purpose

    The purpose of the study is to learn more about whether an ultrasound treatment for epilepsy and anxiety is safe and effective.

    Could this study be right for you?

    • Age: 18-65 years old
    • Treatment resistant Epilepsy (focal or partial-onset seizures)
    • ≥ 3 seizures/month
    • Moderate-to-severe Anxiety

     

     

    Age Range

    18 - 65 years

    Contact Information

    Ohio State Wexner Medical Center
    Shiane Toleson
    614-366-3523
  • Neurodevelopmental Effects of Youth Tackle Football

    Official Title Understanding the Neurodevelopmental Effects of Youth Tackle Football Participation

    Purpose

    In this study we are aiming to identify risk factors for higher exposure to football-related neurotrauma in youth tackle football players and to determine the effects of football-related neurotrauma exposure on neurodevelopment in children with no previous tackle football participation.

    For this specific posting, we are looking for boys ages 8-12 who are non-athletes or athletes who play non-contact sports to serve as control subjects for our fMRI study. 

    Could this study be right for you?

    We are looking for boys ages 8-12 who are either non-athletes or do not participate in any contact sports.

    • Boys must have no metal implanted in the body
    • Have no prior history of head trauma
    • Have no serious health or mental health diagnoses
    • Must not have a fear of enclosed spaces

    Age Range

    8 - 12 years

    Contact Information

    1835 Neil Ave, Columbus
    Nii-Ayi Aryeetey
  • Exploring the Development of the Infant and Fetal Brain

    Official Title Exploring the Connectivity and Functional Organization of the Infant Brain

    Purpose

    The purpose of the study is to investigate how the brain that we are each born with leads to our own unique behavior later in life, and the similarities and differences between maternal and child brains. We are studying infants prenatally and postnatally, following up with them as they grow and develop, and studying their mothers to understand how similar/different they are to their child.

    Could this study be right for you?

    • Infants under 3 years of age, and pregnant persons who are at least 20 weeks pregnant
    • All participants must have no metal implanted in the body
    • Have no significant health conditions or history of serious mental illness
    • Not suffer from a (fear of enclosed spaces)
    • Pregnancies must be without complication.

    Age Range

    Up to 40 years

    Contact Information

    1835 Neil Ave, Columbus
    Anna Quatrale
  • A study assessing the impact of a treatment on anxiety and stress in individuals with memory concerns.

    Official Title Treatment of Stress and Anxiety in mild cognitive impairment (MCI)/Mild Alzheimer's Disease and related dementias (ADRD) and their care partners: A Randomized Controlled Trial

    Purpose

    The purpose of this study is to assess the impact of a treatment on anxiety and stress in individuals with memory concerns and those already with a diagnosis of Mild Cognitive Impairment (MCI), Mild Alzheimer's Disease and related dementias. 

    Could this study be right for you?

    The primary participant must:

    • Be at least 60 years of age
    • Have a “care-partner” that is willing to participate in the full program (such as a spouse, child or a good friend)
    • NOT have a terminal illness or severe motor impairment
    • Be able to use a computer and smartphone and read English at the 6th grade level

    The care partner must:

    • Be at least 18 years of age
    • Be able to use a computer and smartphone and read English at the 6th grade level

    Age Range

    60 - 99 years

    Contact Information

    The Ohio State University, Ohio University, and Florida State University
    Sarah Irvin
    614-379-3173
  • Buckeye Concussion Knowledge Survey (BUCKS)

    Official Title BUckeye Concussion Knowledge Survey (BUCKS)

    Purpose

    The purpose of this study is to examine health outcomes in former Ohio State University athletes who played a varsity sport during their time at OSU. The objective is to determine whether athletes who sustained a concussion have different health outcomes than those who did not sustain a concussion. Any former OSU varsity athlete can participate in a 20-minute online survey.

    Could this study be right for you?

    • Anyone who has played a varsity sport as an undergraduate student at OSU, and they have now graduated (i.e., OSU athlete alumni). There are no other restrictions in terms of age, sex/gender, type of sport, etc.

    Age Range

    18 years and up

    Contact Information

    Stacey Park
    614-292-3300
  • A Study about Eye Teaming, Focusing Ability and Quality of Life

    Official Title Development of Patient-Reported Outcome Measures for Children with Concussion-Related and Non-Concussion-Related Non-Strabismic Binocular Vision, Accommodative and Visual Tracking Problems: Phase 1

    Purpose

    The purpose of this study is to assist in development of a new quality of life survey that can be used to learn more about how eye teaming, focusing ability and eye movement problems affect a child’s life.

    Could this study be right for you?

    • Children experiencing eye teaming, focusing, and eye movement problems (with recent concussion or non-concussed)
    • Children with amblyopia (lazy eye) are excluded

    Age Range

    8 - 17 years

    Contact Information

    Fry Hall, OSU Optometry Clinic
    Marjean Kulp
    614-688-3336
  • A Study About the Development of Learning in African-American/Black Children

    Official Title Ontogenesis of Categorization; Linking development, mechanisms, and biology

    Purpose

    The purpose of this study is to investigate the early development of attention, learning, and memory during childhood. Participation in this study includes 4, 90-minute-long visits to the lab per year. During these visits, your child will play 2-3 fun, computerized games. These games are designed to assess various aspects of their cognitive ability. 

    The duration of the study will last 4 years.

    Could this study be right for you?

    Eligibility Criteria: 

    • African-American/Black children who are 4 years old 

    Age Range

    4 - 4

    Contact Information

    1835 Neil Ave
    The CDL Team
    614-292-0860
  • A Study About Gene Therapy for Early Alzheimer’s Disease (AD) and Mild Cognitive Impairment (MCI)

    Official Title A Phase I Study to Assess the Safety, Tolerability and Preliminary Efficacy of AAV2-BDNF [Adeno-Associated Virus (AAV)-based, Vector-Mediated Delivery of Human Brain Derived Neurotrophic Factor] in Subjects with Early Alzheimer’s Disease and Mild Cognitive Impairment

    Purpose

    The primary aim of this study is to determine whether administration of the nervous system growth factor "Brain-Deruved Neurotrophic Factor" (BDNF) to eligible patients with Alzheimer's disease and Mild Cognitive Impairment is safe and tolerable. This study will be used to determine whether BDNF administration reduces neuronal loss and rebuilds synapses in the brain of patients with Alzheimer's Disease (AD) and Mild Cognitive Impairment (MCI). 

    Could this study be right for you?

    • Male and Females aged 50 years or older
    • Diagnosis of dementia due to Alzheimer's Disease/Diagnosis of Mild Cognitive Impairment (MCI) due to Alzheimer’s Disease
    • A caregiver is available who has frequent contact with the subject, agrees to observe for adverse events, and will accompany the subject to all clinic visits for the duration of the protocol
    • CT or MRI scans within 24 months prior to screening without evidence of an infection, infarction, or other focal 

    Inclusion Criteria varies, please contact Study Coordinator for more information.

    The below Exclusion Criteria apply to both the AD and MCI groups.

    • Any significant neurological disease other than suspected incipient disease
    • History of schizophrenia 
    • History of systemic cancer within the past 18 months (non-metastatic skin cancers are acceptable).
    • Any significant systemic illness or unstable medical conditions which could lead to difficulty complying with the protocol
    • Use of any investigational drugs within thirty days or five half-lives, whichever is longer, prior to screening.

    Exclusion Criteria varies, please contact Study Coordinator for more information. 

    Age Range

    50 and up

    Contact Information

    The Ohio State University Wexner Medical Center
    Andrea Davis